Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

vensobafusp alfa

A fusion protein composed of an engineered immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5), with potential anti-inflammatory and immunomodulatory activities. Upon administration of a vensobafusp alfa, the anti-C5 antibody moiety targets and binds to terminal complement protein C5, thereby blocking the terminal complement pathway of complement activation. The FH1-5 moiety inhibits complement C3b deposition, thereby blocking the alternative pathway of complement activation. This inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-C5 monoclonal antibody/complement factor H 1-5 domain fusion protein KP104
anti-C5 monoclonal antibody/FH SCR 1-5 fusion protein KP104
anti-C5 monoclonal antibody/FH1-5 fusion protein KP104
Code name:KP 104
KP-104
KP1 04
KP1-04
KP104
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search